Cabezas-Cerrato J, Garcia-Estevez D A, Araújo-Vilar D
Servicio de Endocrinologia y Nutrición, C.H.U.S. (General Hospital), Santiago de Compostela, Spain.
Diabetes Metab. 1997 Nov;23(5):402-8.
We investigated glucose metabolism and beta-cell function in normotensive subjects with one essential-hypertensive parent and in subjects with mild/moderate essential hypertension (eHT) before and after 12-week treatment with nitrendipine. The hypertensive-parent group comprised 12 normotensive subjects, and the hypertensive group 15 subjects with mild/moderate eHT. A corresponding control group composed of 20 normotensive subjects was also investigated. All subjects underwent a frequently sampled intravenous glucose tolerance test (FSIGT). Hypertensive subjects underwent FSIGT testing before and after 12 weeks of treatment with nitrendipine (20 mg per day). Insulin sensitivity, glucose effectiveness and beta-cell function were investigated using the minimal model technique on the basis of FSIGT test data. No significant differences were detected in any of the minimal-model parameters either between the hypertensive-parent group and the control, or between the hypertensive group (before nitrendipine treatment) and the control. Twelve weeks of anti-hypertensive treatment with nitrendipine led to an increase in glucose effectiveness and a non-significant increase in glucose tolerance, but had no significant effects on other minimal-model parameters or on the serum lipid profile. Our results suggest that eHT cannot be considered consistently associated with insulin resistance. Nitrendipine treatment appears to have no undesirable effects on peripheral sensitivity to insulin or on beta-cell function. However, the 12-week course led to a 72% increase in glucose effectiveness.
我们研究了有一位原发性高血压父母的血压正常受试者以及轻度/中度原发性高血压(eHT)受试者在使用尼群地平进行12周治疗前后的葡萄糖代谢和β细胞功能。高血压父母组包括12名血压正常的受试者,高血压组包括15名轻度/中度eHT受试者。还对由20名血压正常的受试者组成的相应对照组进行了研究。所有受试者均接受了频繁采样静脉葡萄糖耐量试验(FSIGT)。高血压受试者在使用尼群地平(每天20毫克)治疗12周前后进行了FSIGT测试。基于FSIGT测试数据,使用最小模型技术研究了胰岛素敏感性、葡萄糖效能和β细胞功能。在高血压父母组与对照组之间,或高血压组(尼群地平治疗前)与对照组之间,未检测到任何最小模型参数有显著差异。使用尼群地平进行12周的抗高血压治疗导致葡萄糖效能增加,葡萄糖耐量有非显著性增加,但对其他最小模型参数或血清脂质谱无显著影响。我们的结果表明,不能始终认为eHT与胰岛素抵抗相关。尼群地平治疗似乎对外周胰岛素敏感性或β细胞功能没有不良影响。然而,12周疗程使葡萄糖效能增加了72%。